One last bit worth noting:
"Co-Principal Investigator, Clinical Associate Professor David Packham of the Melbourne Renal Research Group said "Recent recruitment to the trial has been excellent and exceeded expectations."
Older DXB holders will remember that recruitment over a year ago was terribly slow for a long time when the trial commenced. The statement above may indicate that word of DMX200 is spreading??
Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
-0.005(0.91%) |
Mkt cap ! $327.0M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 56.0¢ | 54.0¢ | $620.0K | 1.130M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27049 | 54.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.5¢ | 49999 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| DXB (ASX) Chart |